Nav: Home

BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells

February 15, 2017

OTTAWA, ON - Wednesday, February 15, 2017, 10 a.m. ET - BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer including research aimed at developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada. CAR-Ts are a powerful new tool for treating cancer and have begun to provide hope to patients without other therapeutic options to treat and cure their disease.

CAR-T cell therapy is on the cutting edge of cancer therapeutics and has shown promise in paediatric and adult patients with certain blood cancers such as acute lymphoblastic leukemia and lymphoma.

CAR-T is a promising technology, involving sophisticated manufacturing and expertise. Canada has the basic laboratory infrastructure in place and this new funding will help to fully develop the expertise and capacity required to deliver this technology. BioCanRx is investing in research projects advancing several innovative engineered T cell designs, which will further benefit from this infrastructure and capacity investment, and accelerate delivery of these novel concepts into clinical testing in Canada.

This Canadian capacity development will pave the way to enable Canadian patients to access this new technology, and will give Canadian researchers the necessary resources to deliver on their innovations in CAR-T and other engineered T cell platforms. This CAR-T manufacturing initiative is unique in that the Canadian academic community recognized a gap and stepped up to drive Canadian solutions to meet grassroots efforts taking place in the U.S., China and Europe.

BioCanRx has established an extensive network of investigators and core facilities across the country and is well positioned to bring CAR-T cell treatment to patients in Canada who are in dire need. Leading this capacity building for CAR-T therapies in Canada are Dr. Robert Holt, distinguished scientist, BC Cancer Agency, Head of Sequencing and Head of Quality Systems, Canada's Michael Smith Genome Sciences Centre, Professor, Medical Genetics, University of British Columbia and Professor, Molecular Biology and Biochemistry, Simon Fraser University; Dr. John Bell, Sr. Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Professor, Departments of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa and Scientific Director, BioCanRx; John Webb, Scientist and Project Leader, BC Cancer Agency Deeley Research Centre and Adjunct Associate Professor, University of Victoria; Brad Nelson, Director, Deeley Research Centre, BC Cancer Agency among other researchers.

To help ensure CAR-T cell therapy is brought to patients safely and effectively, BioCanRx is funding a companion Clinical, Social, and Economic Impact project. It will review the existing base of knowledge and involve patient consultation to design a rigorous CAR-T clinical trial protocol ready to implement once the products are ready for a phase 1 clinical trial. Leading this project are Dr. Manoj Lalu, Associate Scientist, Assistant Professor, Clinical Epidemiology and Regenerative Medicine Programs, Ottawa Hospital Research Institute (OHRI), Department of Anesthesiology and Pain Medicine, University of Ottawa; Dr. Dean Fergusson, Director and Senior Scientist, Clinical Epidemiology Program, OHRI; Dr. Natasha Kekre, Assistant Professor, Associate Scientist, Hematologist, Blood and Marrow Transplant Program, OHRI, The Ottawa Hospital, University of Ottawa among other researchers.

Cancer is the leading cause of death in Canada and is responsible for 30% of all deaths. Two out of five Canadians (45% of men and 42% of women) are expected to develop cancer during their lifetimes. One out of four Canadians (29% of men and 24% of women) is expected to die from cancer. (Canadian Cancer Society)

Biotherapeutics - including oncolytic viruses, adoptive cell therapy and therapeutic antibodies - are among the most promising cancer therapies to emerge in the last decade and are often referred to as a fourth pillar for cancer treatment. BioCanRx is building a research portfolio of these immunotherapies but what sets it apart is its commitment to combination therapies. Combining biotherapeutics approaches can amplify effectiveness and result in significantly better outcomes compared to the benefits of an individual biotherapy used on its own.

Today's funding announcement will support 16 national research teams comprised of researchers, clinicians and trainees working to find improved treatment options and outcomes for cancer patients. BioCanRx's funded partnerships will strengthen the coordination of research and resources in Canada to further develop a variety of cancer immunotherapy platforms. The research proposed could lead to significantly better outcomes for cancer patients and, potentially, curative approaches to their cancer.

Quick Facts:
  • The teams receiving funding are successful applicants in BioCanRx's open funding call.

  • Research projects funded by BioCanRx are evaluated through a rigorous peer review process conducted by the Research Management Committee, which includes international academics and Canadian industry experts.

  • Projects are selected based on their scientific excellence and their alignment with the network's collaborative mission.

  • BioCanRx's research program invests in late-stage preclinical and translational research projects that will develop the most promising cancer biotherapies -- therapies that are cost-effective, less toxic and, most importantly, potentially curative. BioCanRx also supports research into the social and economic issues surrounding the development of biotherapeutics.

  • Since its inception in January 2015, BioCanRx is funding a total of 30 projects including three clinical trials. More information about these projects can be found on the BioCanRx website.

  • The next deadline for BioCanRx's open funding call is March 1, 2017. Full details can be found at BioCanRx's Apply for funding page.


"CAR-T technology is a new and exciting development that's really taken the world by storm. We know now that by taking T cells out of patients, and reengineering them as it were in a test tube, we can get them to have dramatic responses in some kinds of cancer patients. Unfortunately, in Canada, we don't have this technology available to us to be used widely across the country. So this funding will allow us to be in a position to manufacture this kind of product ourselves, get our own scientists engaged in being able to actually test their ideas, exploiting this new technology and, we hope, to bring something to the Canadian people much faster than it would be otherwise."

Dr. John Bell
Scientific Director, BioCanRx

"BioCanRx is committed to investing in collaborative research projects aimed at improving the health and lives of thousands of Canadians currently living with cancer. Collaboration is critical to ensuring better use of study results and providing a measurable difference. We are confident that this research will address existing gaps in moving this platform forward."

Ken Newport
Chair, BioCanRx Board of Directors

"The impact cancer is having on our population is devastating. While we have made enormous progress in treating cancer, much more needs to be understood about better ways to fight this disease and ultimately cure those afflicted. BioCanRx is committed to supporting research excellence and its translation into health benefits for Canadians. We hope to one day announce that there has been a significant reduction in deaths related to cancer thanks to research support by our network and partners.

Dr. Stéphanie Michaud
President and CEO, BioCanRx

"My congratulations to the sixteen national teams receiving funding through BioCanRx's research program. By advancing the field of immunotherapies, your work will ultimately be able to support innovative and promising new cancer treatments for Canadians."

The Honourable Jane Philpott
Canada's Minister of Health

"Canadian scientists are world-renowned for their research into how the body's immune system can be used to treat cancer. This emerging field of medical research has the potential to save lives as well as improve them. It also creates better jobs and opportunities for Canadians working in the life-sciences sector. The funding being allocated to Canadian research teams through BioCanRx will allow this promising research to move beyond laboratories and into clinics, where it can actually make a difference in people's lives. That's how innovation makes a better Canada."

The Honourable Navdeep Bains
Canada's Minister of Innovation, Science and Economic Development

"The use of CAR-T cells represents a significant and very recent advancement in cancer treatment and has become a powerful tool for converting incurable into curable. Unfortunately, the use of this therapy in Canada has been limited by our access to the product, forcing cancer patients to travel far and wide, usually outside Canada, to access this therapy in US clinical trials. A home grown Canadian solution is long overdue - BioCanRx has taken a bold step in ensuring this innovative new therapy is available for Canadians in Canada."

Patrick Sullivan
Childhood cancer advocate, President, Team Finn Foundation and founding member of Ac2orn (Advocacy for Canadian Oncology Research Network)
Link for fact sheets, video clips and photos:

For further information:

Nancy Boyle, Director, Communications, Marketing & Engagement, BioCanRx
613-739-6203 /

Danielle Jones, Officer, Communications, Marketing & Engagement, BioCanRx
613-739-6824 /

Kelley Parato, Director, Scientific Affairs, BioCanRx
613-739-6595 /

About BioCanRX - Biotherapeutics for Cancer Treatment

The BioCanRx network is accelerating to the clinic Canada's most promising and innovative cancer biotherapeutics designed to save lives and enable a better quality of life. BioCanRx invests in Canadian innovations and the best the field has to offer, always looking for a clear path to the clinic for the benefit of patients. BioCanRx works in partnership with industry, charities and other agencies to translate immune-based technologies from the lab into early phase clinical trials, and addresses socio-economic considerations necessary for their adoption by health-care systems. The network is developing and attracting the talent needed for a thriving health biotechnology sector in Canada. BioCanRx is provided funding from the federal government's Networks of Centres of Excellence, and support from industry, the provinces and many national charities. 

BioCanRx - Biotherapeutics for Cancer Treatment

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at